Toray Industries, Inc.

Nanotheta Co., Ltd.

Hajimu Kurumatani

Hisanori Wakita

Masafumi Isogaya

Nobutaka Ida

Ayako Kawashima

Yoshihisa Yamane

Masahiko Takenaka

Mitsutaka Tamura

Koji Miyata

Shinji Takeoka

Yuichi Mori

Shigeru Aoki

Tsutomu Nakamura

Shintaro Nishio

Katsuhiko Iseki

Motoyuki Yajima

Toru Arakane

Susumu Matsuda

Makoto Nakahara

Hiroshi Kataoka

Shoji Nagaoka

Mie Kainoh

Hiroki Kumagai

Reiji Kasukawa

Tasuku Okamoto

Shinya Otsubo

Masayuki Miyata

Yuji Ueno

Kumi Oyama

Mitsuko Miyamoto

Rie Sasaki

Masaharu Shiga

Takumi Matsuura

Keiko Nakahara

Mamoru Nishiura

Yuji Kuwabara

Gozoh Tsujimoto

Kyoko Yamada

Masanobu Takeda

Hiroshi Koike

Motohiro Suzuki

Takashi Ikari

Yuzuru Matsumura

Fuko Matsuda

Masateru Yamada

A carboxylic acid-type lipid can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each include the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane. A carboxylic acid-type lipid is selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle includes the carboxylic acid-type lipid, a lipid membrane includes the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane.

Carboxylic acid-type lipid, and lipid particle and lipid membrane each comprising carboxylic acid-type lipid

A therapeutic method for a cat treats chronic kidney disease to inhibit progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat or improve the overall survival rate or the observed survival rate. The therapeutic method for a cat with chronic kidney disease inhibits progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 or 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 μg of the compound represented by formula (I) daily: wherein R represents hydrogen or a pharmacologically acceptable cation.

Therapeutic method for cat with chronic kidney disease

An agent enhances the therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

Fortifier

A method of ameliorating symptoms of uremia includes administering a therapeutic agent including beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Canidae, wherein an effective dosage is a dosage that does not significantly lower blood pressure.

Method of ameliorating uremia

A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin Iderivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.

Therapeutic agent and treatment method for ameliorating uremia

An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

Combination therapy for the treatment of chronic renal failure with an angiotensin II receptor antagonist and beraprost

A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin Iderivative, and also a method for treatment of renal failure using the same.

Therapeutic agent for renal failure

The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.

Therapeutic agent for chronic renal failure

A method of inhibiting mammalian C&mdash;C chemokine production by using a mammalian C&mdash;C chemokine synthesis inhibitor containing a prostaglandin I derivative as an active component to treat a variety of circulatory diseases, inflammation, allergic diseases, and renal diseases.

C-C chemokine synthesis inhibitor

The present invention provides a protective agent for nervous system structural cells comprising a prostaglandin I derivative, preferably a prostaglandin I derivative, particularly beraplost, as an active component. This medicine exhibits excellent effects as a protective agent for nervous system structural cells, and is effective as an excellent agent for preventing or curing cerebrovascular disorder, cerebral nerve cell disorder, ischemic cerebral disorder, dementia, and peripheral nerve disorder due to diabetic or the like.

Protective agent for nervous system structural cells

An ophthalmic preparation which exhibits excellent pharmacological effects for various ophthalmic diseases is disclosed. The ophthalmic preparation according to the present invention contains a 4,8-inter-m-phenylene prostaglandin I,derivative represented by the formula (I):

Ophthalmic preparations

Ocular depressor

Agent for treating cor pulmonale

A method of treatment for diabetic neuropathy using combined administration of a formulation including as an active ingredient a prostaglandin I derivative, especially a prostaglandin I.sub.2 derivative with an anti-diabetic agent is applied to hypofunction of motor nerve and sensory nerve to which conventional anti-diabetic agents do not provide sufficient treatments, with nerve conduction velocities improved.

Method of treatment for diabetic neuropathy

The present invention is implantation materials comprising an anti-thrombogenic material contained in the surface in contact with blood, of a porous substrate with its voids filled with denatured albumin or a biodegradable polyester. Since they are excellent in anti-thrombogenic property and allow the positive introduction of cells into the implantation materials, they can prevent thrombogenesis for long periods of time. Especially even if they are used as artificial small diameter blood vessels of less than 6 mm in inner diameter, they show excellent patency.

Implantation materials

Growing community of inventors

Kanagawa, Japan

Hajimu Kurumatani